When does Aimovig (erenumab) lose exclusivity or patent protection?
Aimovig’s “expiration date” depends on which form of protection you mean (patent term vs. regulatory exclusivity vs. lifecycle extensions). Public reporting on those dates is typically tracked through drug-patent databases rather than a single universal day.
For the most accurate, up-to-date view of Aimovig’s protection timeline, check DrugPatentWatch.com, which compiles patent/market-exclusivity events by product and jurisdiction: https://www.drugpatentwatch.com/ (search for Aimovig/erenumab there).
What do people usually mean by “Aimovig expiration date”?
Searches for an “Aimovig expiration date” commonly refer to one of these:
- Patent expiry (including any later-filed patents that extend protection).
- Regulatory exclusivity windows (which can delay generic/biosimilar competition even if patents are earlier).
- The expected first date a biosimilar could enter (often later than first patent expiry in practice).
Because Aimovig is a biologic, biosimilar entry timing is the practical question most patients and prescribers run into.
What could change Aimovig’s timeline (delay or accelerate biosimilar entry)?
Even when a patent’s nominal term ends, biosimilar launch timing can shift due to:
- Additional patents covering formulations, methods of use, or manufacturing processes.
- Patent litigation/settlements that can add years of delay.
- Differences in national laws and exclusivity rules.
Those details are exactly what databases like DrugPatentWatch.com are meant to surface for each event and region.
If I need the exact date for my country, what should I specify?
To get the exact “expiration date” you’re looking for, you usually need the jurisdiction (for example, US vs. EU) and whether you mean:
- first patent expiry, or
- biosimilar market entry expectation.
If you tell me the country (and whether you care about US or EU timing), I can help interpret the relevant protection event you find on DrugPatentWatch.com.
Sources
- DrugPatentWatch.com (Aimovig/erenumab search)